Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • How three companies are collaborating to tackle an epidemic
    • News

    How three companies are collaborating to tackle an epidemic

    Three companies are joining forces to help tackle one of the most serious public health challenges of our time – the HIV/AIDS epidemic. Viatris and Atomo Diagnostics (ASX: AT1) have announced an agreement with Unitaid to increase accessibility of HIV self-testing in low-and middle-income countries (LMICs).  The announcement represents significant market expansion, with Unitaid committing

    Read More
    Public
  • Raiz adds property as alternative asset class for micro-investing, joins crypto
    • News

    Raiz adds property as alternative asset class for micro-investing, joins crypto

    Privy to the investment patterns of millennials seeking alternative asset classes, micro-investing fintech Raiz (ASX: RZI) is creating opportunities to enter the property market via ownership of a solitary brick in a house through the addition of residential property to their portfolios. The addition of residential property to the Raiz portfolios continues a trend the

    Read More
    Public
  • You beauty! Health and wellness stocks that deliver prosperity and vitality
    • Opinion

    You beauty! Health and wellness stocks that deliver prosperity and vitality

    It seems the only advertisers these days are Harvey Norman, sports betting shops and Chemist Warehouse and Priceline with their pages of pills and unguents. Indeed, the term “health and wellness” might be overused and even tautologous, but tell that to the average household that spend many billions of dollars annually on cosmetics, dietary supplements

    Read More
    Public
  • Fund Manager Meeting Notes – Rhythm Biosciences (ASX: RHY)
    • Opinion

    Fund Manager Meeting Notes – Rhythm Biosciences (ASX: RHY)

    We recently had a one-on-one meeting with Mr. Glenn Gilbert, CEO of Rhythm Biosciences (ASX: RHY). As we do not cover the stock, the main purpose of this call was to get an initial understanding of the Company’s business model as we develop our knowledge on the stock. RHY is a cancer diagnostics technology developer,

    Read More
    Public
  • Do you really own your shares?
    • Opinion

    Do you really own your shares?

    The global pandemic affected almost every aspect of modern life, and the stock market was no exception. The stock market crash early in 2020 saw an influx of retail investors and a huge increase in the number of accounts opened on trading apps. While investing is almost always a positive step towards financial freedom, experts

    Read More
    Public
  • Latitude IPO successful but how big will the exit selldown be?
    • Opinion

    Latitude IPO successful but how big will the exit selldown be?

    The saying ‘third time’s a charm’ rings true for financial services company Latitude (ASX: LFS) who finally made their entrance to the public market last week after cementing themselves as the biggest ASX float of 2021   This year’s offering marked Latitude’s third attempt at an IPO. Their first attempt was stalled in 2018 by investor

    Read More
    Public
  • «
  • ‹
  • 509
  • 510
  • 511
  • 512
  • 513
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.